Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 5/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.48 |
| ▸ | RELA | Q04206 | 5/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12951314 | 0.72 | NFKB1 (0.51) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL2134159 | 0.72 | NFKB1 (0.51) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL31454795 | 0.72 | NFKB1 (0.51) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL28572940 | 0.72 | NFKB1 (0.51) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL13334908 | 0.72 | NFKB1 (0.51) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL2134157 | 0.72 | NFKB1 (0.51) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL4146153 | 0.72 | NFKB1 (0.51) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL19730161 | 0.70 | CYP3A4 (0.33) | — | |
| SCHEMBL27476940 | 0.69 | NFKB1 (0.59) | NFKB1NFKB2RELAKDM1ABTK | |
| SCHEMBL30449581 | 0.69 | NFKB1 (0.48) | NFKB1NFKB2RELAKDM1ABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12173026-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2024-12-24 | — | — | US | disclosed |
| CN-112805006-B | PRMT5 inhibitors | 默沙东有限责任公司 | 2024-09-24 | — | — | CN | disclosed |
| US-20220363707-A1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363707-A1 | PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | NFKB1 1576/4885NFKB2 3805/4885RELA 3427/4885 |
| US-12173026-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | NFKB1 1576/4885NFKB2 3805/4885RELA 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.